Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China
NCT ID: NCT05431803
Last Updated: 2025-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
129 participants
OBSERVATIONAL
2022-06-30
2024-12-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
NCT02493517
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
NCT00499993
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
NCT00234572
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
NCT00517491
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
NCT00210457
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with serum IGF-1 level above the ULN for age and sex, and serum fasting GH level above 2.5 μg/L
* Participants with acromegaly who are naïve to LAN treatment and about to initiate LAN
Exclusion Criteria
* Pregnant participants
* Participants with hypersensitivity to somatostatin or related peptides or to any of the excipients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical, Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Union Medical College Hospital (PUMCH)
Beijing, , China
Peking University Third Hospital (PUH3)
Beijing, , China
Xiangya Hospital Central South University (XYHCSU)
Changsha, , China
West China Hospital，Sichuan University (WCH)
Chengdu, , China
The First Affiliated Hospital,Sun Yat-sen University (FAHSYSU)
Guangzhou, , China
The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU)
Hangzhou, , China
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School (NJDTH)
Nanjing, , China
The First Hospital of China Medical University (CMU1H)
Shenyang, , China
The Second Hospital of Hebei Medical University (HB2H)
Shijiazhuang, , China
Affiliated Hospital of Wenzhou Medical University (FAHWMU)
Wenzhou, , China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology (TJH HUST)
Wuhan, , China
The First Affiliated Hospital of Zhengzhou University (FAHZZU)
Zhengzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLIN-52030-455
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.